Active site geometry stabilization of a presenilin homolog by the lipid bilayer promotes intramembrane proteolysis

Lukas P. Feilen¹, Shu-Yu Chen², Akio Fukumori³, Regina Feederle^{1,4}, Martin Zacharias², Harald Steiner^{1,5,*}

¹German Center for Neurodegenerative Diseases (DZNE), Munich, Germany

²Physics Department T38, Technical University of Munich, Garching, Germany

³Department of Pharmacotherapeutics II, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Japan

⁴Institute for Diabetes and Obesity, Monoclonal Antibody Core Facility, Helmholtz Munich, German Research Center for Environmental Health, Neuherberg, Germany

⁵Biomedical Center (BMC), Division of Metabolic Biochemistry, Faculty of Medicine, LMU Munich, Germany

*Correspondence: harald.steiner@med.uni-muenchen.de

Keywords

Amyloid β -peptide, intramembrane proteolysis, presenilin, PSH, γ -secretase

ABSTRACT

Cleavage of membrane proteins in the lipid bilayer by intramembrane proteases is crucial for health and disease. Although different lipid environments can potentially modulate their activity, how this is linked to their structural dynamics is unclear. Here we show that the carboxy-peptidase-like activity of the archaeal intramembrane protease PSH, a homolog of the Alzheimer's disease-associated presenilin/ γ -secretase is impaired in micelles and promoted in a lipid bilayer. Comparative molecular dynamics simulations revealed that important elements for substrate binding such as transmembrane domain 6a of PSH are more labile in micelles and stabilized in the lipid bilayer. Moreover, consistent with an enhanced interaction of PSH with a transition-state analog inhibitor, the bilayer promoted the formation of the enzyme's catalytic active site geometry. Our data indicate that the lipid environment of an intramembrane protease plays a critical role in structural stabilization and active site arrangement of the enzyme-substrate complex thereby promoting intramembrane proteolysis.

INTRODUCTION

Intramembrane proteolysis is a crucial cellular mechanism underlying many fundamental physiological processes^{1,2}. It is also involved in pathological conditions, most prominently in Alzheimer's disease (AD). Here, intramembrane cleavage within the transmembrane domain (TMD) of the amyloid precursor protein (APP) derived C99 substrate by γ -secretase results in the release of a variety of amyloid β -peptide (A β) species³. The longer forms, A β 42 and A β 43, are toxic to neurons and believed to trigger the onset of AD⁴. γ -Secretase is a membrane-embedded protein complex consisting of four components⁵. The catalytic subunit presenilin is an aspartyl intramembrane protease⁶⁻¹⁰ present in the mammalian γ -secretase complexes as either presenilin-1 (PS1) or presenilin-2 variant^{11,12}. Mutations in PS1 are the major cause of familial AD (FAD) and cause an imbalance in the production of A β species that leads to relative increases of the longer forms over the normally major form A β 40³. Presenilins are evolutionary highly conserved proteins and related to the signal peptide peptidase (SPP)¹³ family of intramembrane proteases¹⁴. Ancestral precursors of presenilin and SPP exist in several archaea¹⁵ and share key signature motifs including the protease family-defining GxGD active site motif with presenilin and SPP⁸. The archaeal homolog from *Methanoculleus marisnigri* JR1 termed presenilin/SPP homolog (PSH) is capable of cleaving C99 and several other substrates¹⁵⁻¹⁸. Similar to presenilin in the γ -secretase complex, PSH appears to cleave C99 in a sequential manner starting by initial ϵ -site cleavages between L49 and V50 (ϵ 49) or T48 and L49 (ϵ 48) followed by the release of various A β species from stepwise carboxy-terminal trimming cleavages^{16,19}. However, in contrast to presenilin, which requires complex formation with the other γ -secretase complex components for activity²⁰⁻²², PSH is active without accessory components. The crystal structure of PSH revealed first important insights into aspartyl intramembrane

proteases showing that the two catalytic aspartate residues of the active site in TMD6 and TMD7 directly face each other and locate in a water-accessible cavity²³. Subsequent cryo-electron microscopy (cryo-EM) structural analysis of γ -secretase showed that presenilin adopts a structure in the complex very similar to that of PSH²⁴ with nearly identical positions of the catalytic residues²⁵. Further cryo-EM studies showed that binding of APP and Notch substrates causes major conformational changes in both enzyme and substrate^{26,27}. These led to an enzyme-substrate complex (E-S) with an extended TMD6 by formation of a new and stable TMD6a helix as well as a hybrid β -sheet between enzyme and substrate that causes unfolding of the ϵ -cleavage site region in the substrate^{26,27}. Interestingly, formation of the TMD6a helix was also observed by cryo-EM upon inhibitor binding thus partially mimicking the substrate-bound state^{28,29}.

The very similar structural folds of presenilin and PSH and the ability to cleave C99 in the TMD at the same sites as γ -secretase^{15,16} make PSH an attractive model for the intrinsic protease activity of presenilin. To gain basic insights into the enzymatic workings of presenilin proteases, we thus set out to characterize the influence of two fundamentally different hydrophobic environments on the activity of PSH and asked if cleavage of C99 by the solubilized enzyme in detergent micelles would differ from a lipid-reconstituted state and if so, whether such differences could be correlated with the structural dynamics of this prototype presenilin protease or its E-S. Although the influence of lipids on the activity of presenilin and other intramembrane proteases is well documented³⁰, there are so far no studies in which biochemically determined activities of these proteases were linked with structural information that could explain how lipids, in particular a membrane bilayer environment, affect intramembrane protease structural dynamics and enzyme function. Since presenilins are not active in detergent micelles without lipids³¹ this

critical question can however not be addressed for γ -secretase directly and requires a suitable model protease such as PSH. We found that detergent-solubilized PSH has a reduced carboxy-terminal trimming activity, i.e. processivity, compared to γ -secretase giving rise to an increased production of very long A β species such as A β 46. Strikingly, the reconstitution of PSH into a lipid bilayer strongly promoted the protease processivity to shorter A β species such as A β 38 highlighting the important role of the lipid membrane environment for intramembrane proteolysis. Furthermore, it enhanced the binding of a transition-state analog (TSA) γ -secretase inhibitor (GSI) affinity probe suggesting a more stable active site conformation in the lipid bilayer. These biochemical studies were accompanied by comparative modeling and molecular dynamics (MD) simulations to study the effect of detergent micelle and membrane lipid environment on substrate-bound PSH. In good agreement with the experimental data, the computational data suggest that the stabilization of TMD6a and the active site can explain the increased processivity and inhibitor binding in the membrane bilayer. Mutational analysis confirmed the assumed critical functional role of β -sheet and TMD6a corroborating the computational analysis of substrate-bound PSH. Collectively, these data provide insights into how structural adaptations occurring in response to changes in the hydrophobic environment from a micellar membrane mimetic to a real lipid bilayer translate into activity changes of an intramembrane protease. Moreover, with general implications for intramembrane proteolysis, they show how a lipid bilayer allows the formation of a stabilized active site geometry poised for substrate cleavage.

RESULTS

PSH cleaves APP C99 to longer A β species

To get insights into the intrinsic protease activity of presenilin, we set out to further characterize the intramembrane cleavage of C99 by PSH (**Figure 1A**). Consistent with previous findings ¹⁶, n-dodecyl β -D-maltoside (DDM)-solubilized, His-affinity-purified PSH could cleave the C99-based APP C100-His₆ substrate ²¹ as demonstrated by the generation of the APP intracellular domain (AICD) and A β cleavage products (**Figure 1B**). Cleavage was inhibited by the TSA GSI L-685,458 ³² (**Figure 1B**) although much higher, micromolar concentrations were needed for efficient inhibition compared to those known for γ -secretase ^{7,32}. Analysis of the A β profile using Tris-Bicine urea SDS-PAGE (**Figure 1C**) and MALDI-TOF mass spectrometry (**Figure 1D, Figure 1 – figure supplement 1**) showed that A β 40 and A β 42 were the major A β species produced with a preference of A β 42 over A β 40. Interestingly, besides the increased generation of A β 42 even longer A β species such as A β 46 were relatively abundant. This suggests that PSH cleaves C99 at the same sites as γ -secretase but with reduced processivity.

Lipid membrane enhances the processivity of PSH

We next investigated how a membrane environment of PSH influences the cleavage and processivity of the protease. Previous studies have shown that γ -secretase activity is dependent on the membrane environment as modulations of the lipid composition and/or bulk membrane properties in cell-free assays affected total activity as well as the ratios of the A β species generated ³³⁻³⁶. Furthermore, it was also shown that varying the pH in cell-free assays can modulate the total activity as well as the processivity of γ -secretase ³⁷. To investigate whether and how PSH cleavage of C99 would respond to a change from the micellar environment in DDM to a lipid bilayer environment, PSH was reconstituted in defined small unilamellar vesicles (SUVs) composed of palmitoyl-oleoyl PC (POPC), the most abundant

phospholipid of biological membranes (**Figure 2 – figure supplement 1A, B**). We then performed PSH *in vitro* assays with DDM-solubilized or POPC-reconstituted PSH in a pH range from 5.5 to 9.0. As shown in **Figure 2A**, the total activity was highest in the mild acidic to mild alkaline pH range and sharply dropped at pH values above 8.0. The pH optima for both conditions were very similar and lying around pH 7.0. However, compared to the DDM-solubilized enzyme, the processivity of PSH was strongly promoted in the lipid bilayer environment of the POPC SUVs as seen by a strongly increased production of A β 38 and A β 40 and the strong reduction of longer A β species (**Figure 2B**). Interestingly, the processivity of the reconstituted PSH appeared to be more reduced at alkaline pH values as judged from the appearance of A β species longer than A β 42 (**Figure 2B**) at pH 7.5 and higher. A direct comparison of the A β profiles at pH 7.0 confirmed the increased processivity of PSH in the POPC lipid bilayer (**Figure 2C, Figure 2 – figure supplement 2A**). Finally, we investigated the initial ϵ -site cleavages of C99 by PSH in DDM micelles or POPC vesicles at this pH. Mass spectrometry analysis showed that C99 was cleaved in both conditions at the ϵ 49 and ϵ 48 cleavage sites resulting in the release of the two N-terminally distinct AICD50 (ϵ 49) and AICD51 (ϵ 48) species (**Figure 2D, Figure 2 – figure supplement 2B**). Collectively, these data show that the lipid environment increases the processivity of PSH in cleaving C99.

Enhanced processivity of PSH is independent of the APP substrate N-terminus

Since the activities of DDM-solubilized and reconstituted PSH clearly differed, particularly in the processivity, we next sought to understand the underlying basis for this behavior at the level of its structural dynamics. Since there is no structure of PSH in complex with C99 available and structural investigations on γ -secretase in complex with an APP substrate were so far only performed with C83, an N-terminally

shorter alternative C-terminal APP fragment generated by α -secretase³⁸, we first tested whether C83 is processed similarly than C99. We thus analysed its cleavage by PSH in DDM micelles and the POPC bilayer at pH 7.0. C83 was cleaved by PSH in both conditions resulting in the generation of an AICD and the A β -equivalent cleavage product p3³⁸ (**Figure 3A**). As judged from the processivity-reflecting ratios of p3 species ending at position 40 and 42, in contrast to the DDM micelle environment, the POPC bilayer enhanced the processivity and caused an increase in the relative production of shorter p3 species (**Figure 3B**). The increase in processivity was similar to that observed under these conditions for the corresponding A β species produced from C99 (**Figure 3C**). These data show that the increased processivity in the POPC environment is independent of the N-terminus of the substrate and that C83 and C99 behave comparable in both environments, so that C83 should be suitable as C99 surrogate for structural modelling and molecular dynamics simulations of PSH in complex with a substrate using information from the C83-bound γ -secretase.

Structural modeling shows key features of substrate-bound γ -secretase in PSH

Since no experimental structure of the substrate-bound (holo) PSH is available, we generated 3 different starting structures, model 1, 2 and 3, for the PSH holo form using template-based modeling by assuming that PSH binds its substrate in a similar way as PS1. Since the PSH crystal structure²³ (PDB 4HYG) misses several residues and loop segments in its substrate-free (apo) form, it is necessary to include the cryo-EM structure of holo PS1 bound to the C83 γ -secretase substrate²⁶ (PDB 6IYC) as an additional template. In model 1, we used the entire holo PS1 including the C83 substrate as template whereas in model 2 and 3 most of the apo PSH structure was included and only different parts of missing loops segments were

modelled based on the 6IYC template (including the C83 substrate, see Materials and Methods for details). The overall structures of our holo PSH models are close to the experimentally determined apo PSH crystal structure²³ but include several residues and loop segments that are missing in the apo crystal structure (**Table 1, Figure 4 – figure supplement 1A, B, Figure 4 – figure supplement 2**). In particular, as exemplified for model 2 (**Figure 4A**), it includes the TMD6a helix (residues H171-E177) C-terminal of TMD6 and the hybrid β -sheet formed between the β 2-strand (A213-G217) and the β 3-strand (V50-K54) of the substrate, which is stabilized by backbone interactions with residue Q272 preceding TMD9 (**Figure 4B**). These two structural elements were also found in the γ -secretase complexes with bound C83²⁶ or Notch1²⁷ (PDB 6IDF) and were not present in the substrate-free γ -secretase complex. In addition, a salt bridge between R70 and E181 in the homology-modeled PSH (**Figure 4C**) replaced the hydrogen bond partners Y159 and R278 of the substrate-bound γ -secretase structure (**Figure 4D**). Thus, key features for substrate interaction (TMD6a and hybrid β -sheet) known from the γ -secretase–substrate complexes are analogously found in our models of the PSH–C83 complex.

Verification of β 2-strand in the substrate-bound PSH models

Comparative modeling is sensitive to the choice of the templates and how the sequences are aligned together. A template with low quality or a sequence alignment with high uncertainties can lead to an unrealistic protein structure. Therefore, it is necessary to verify the presence of specific structural features in our substrate-bound PSH models that were observed in the substrate-bound PS1 structure. In case of γ -secretase, the deletion of the β 2-strand (R377-L381) impaired the activity of the enzyme towards C83 and Notch1^{26,27}. To investigate whether this structural element is of similar functional importance in PSH, we mutated amino acid

residues A213, F214 and V215 within the putative PSH β 2-strand to prolines. Similar as done for PS1^{26,27}, we also deleted amino acid residues A213 to M216 and A213 to G217. When assessed for their enzymatic activity, the three mutants as well as the two deletion constructs showed clearly, and mainly strongly, decreased activities compared to wild type (WT) PSH in both DDM micelle or POPC bilayer conditions (**Figure 4E**). These results suggest that as the residues 213 to 216/217 are important for the activity of the protease they might indeed form the β 2-strand observed in our structural models.

Comparative molecular dynamics simulations of PSH in micelle and membrane environment reveals reduced PSH flexibility in the lipid bilayer

To get insight into the molecular details on how micelle and membrane environments might influence PSH conformational dynamics, the constructed C83-bound PSH models were embedded in DDM micelle (150 DDM molecules) or POPC bilayer (302 POPC molecules) environments and in each case three simulations with different distribution of starting velocities were performed (each simulation length: 0.6 μ s). In total, 6 systems were constructed and 18 trajectories were generated *in silico*.

Snapshots of the PSH holo form in both environments are shown for model 2 in **Figure 5A**. All simulated systems stayed overall close to the starting structures with root-mean-square deviations (RMSD) relative to the start structure of about or less than 4.0 Å and an overall lower RMSD for all model 2 simulations (**Figure 5 – figure supplement 1A**). Larger deviations were observed for all model 1 simulations and for one trajectory for model 3. It is likely that model 1 is less realistic than model 2 and 3 because it is entirely based on the PS1 template structure and is missing structural information from PSH.

We first analyzed the substrate mobility and interaction with PSH during the simulations in both environments. Stable substrate binding near the active site region involves the interaction of the β 2-strand with the β 3-strand at the C-terminus of the C83 substrate, which is required for substrate cleavage. The overall β -sheet interaction in terms of hydrogen bonds (H-bonds) was found to be similar in both the micelles and membrane environments except for model 3 where the H-bonds are more frequently formed in the bilayer (**Figure 5B**). We next investigated the root-mean-square fluctuation (RMSF) profile and the water accessibility of residues in the C83 substrate TMD during the simulations of the holo PSH. Both RMSF and water accessibility for each amino acid were not much different in both environments (**Figure 5C, D**). Notably, the substrate remained in a dry region from G37 to V46 and abruptly gained an increase in water accessibility around T48 and L49, which correspond to the initial ϵ -cleavage sites of C83 (and C99).

To quantitatively evaluate the flexible regions of PSH, RMSF profiles of each residue along the PSH sequence were calculated (**Figure 5E**). In all three models, larger fluctuations of hydrophilic loop 1 (HL1, between TMD1 and 2) were observed in DDM compared to POPC (**Figure 5E**). Similarly, the atomic fluctuations of TMD6a in model 1 and 2 were reduced in POPC but no differences in the two environments were observed for TMD6a in model 3. In both environments, the atomic fluctuations of residues C-terminal of TMD6a stayed reduced in model 1 while they increased in model 3. In contrast to these models, the atomic fluctuations of these residues stayed reduced in POPC and increased in DDM in model 2 (**Figure 5E, Figure 5 – figure supplement 1B**). Furthermore, secondary structure analysis showed that TMD6a is mostly unfolded in model 1 and stable in model 3 (**Figure 5 – figure supplement 2A, C**). Strikingly, when model 2 is placed in the micelle environment, TMD6a of substrate-bound PSH underwent a conformational transition between an

α -helix and a loop structure (**Figure 5 – figure supplement 2B**), while this transition was not observed for TMD6a in the POPC bilayer showing that the membrane environment stabilizes TMD6a (**Figure 5 – figure supplement 2B**).

Despite the high structural similarity between the starting structures of model 2 and model 3 (RMSD = 0.163, **Figure 4 – figure supplement 1B**), a difference in TMD6a positioning was observed during the simulations of these two models in the POPC environment. While TMD6a is located closer to C83 in model 2, it is located further away from C83 in model 3 (**Figure 5 – figure supplement 3A**). In addition, when we directly compared the RMSF profiles of models 2 and 3 (**Figure 5E**) with each other, we observed that the residues immediately C-terminal of TMD6a are slightly more mobile in model 3 (**Figure 5 – figure supplement 3B, C**). Because these residues are spatially close to HL4 between TMD4 and TMD5, HL4 also becomes more flexible in model 3 (**Figure 5 – figure supplement 3B**). In fact, the conformational discrepancy in these regions arise from the model building of the two models which were built differently for residues A163 to R193 and E210 to G219 (**Table 1**, see Materials and Methods for details). With a closer contact between TMD6a and C83 as well as an overall lower RMSD for model 2, we justified that model 2 may describe the dynamics of the PSH-C83 complex best so that model 2 is, therefore, mainly used for our following analysis.

DDM insertion leads to an unwinding of PSH TMD6a

The biochemical cleavage data as well as the fluctuations in the MD simulations indicate a potential weakening of the E-S interaction in the micelle environment. This might explain the remarkable shift in processivity of PSH in the presence of a membrane lipid bilayer. In our PSH models, TMD6a creates a hydrophobic patch (formed by residues M172, I173, L175 and A176) that contacts the C83 substrate in

the ϵ -cleavage site region (e.g. V50 and L52, **Figure 6A**). Similar interactions are found in the experimentally resolved C83-bound and Notch1-bound γ -secretase structures^{26,27}, as well in the GSI-bound γ -secretase structures²⁹ (**Figure 6 – figure supplement 1A-D**). To gain a more detailed mechanistic view on how DDM and POPC molecules modulate the E-S stability, we calculated the structural properties of these molecules and investigated how these interact with PSH and C83. In the bilayer environment, the simulations indicate that POPC molecules are well ordered as indicated by a high lipid order parameter (**Figure 6 – figure supplement 2A, B**) and the computed area per lipid of $\sim 68 \text{ \AA}^2$ is close to the experimentally determined value of $64.3 \text{ \AA}^2$ ³⁹ (**Figure 6 – figure supplement 2C**). In contrast, in the micelle environment, DDM molecules are more mobile and can change their orientation more freely, as indicated by the lower lipid order parameter for DDM compared to POPC (**Figure 6 – figure supplement 2A, B**). In a larger micelle environment, with 50% more DDM molecules (225 DDM molecules, **Figure 6 – figure supplement 3A**) the lipid order parameter of DDM improved (**Figure 6 figure supplement 3B**). Nevertheless, the number of H-bonds in the β -sheet (**Figure 6 – figure supplement 3C**), the RSMF profile (**Figure 6 – figure supplement 3D**) and the water accessibility in the C83 substrate (**Figure 6 – figure supplement 3E**) did not differ from the respective values in the smaller DDM micelle (150 DDM molecules). The atomic fluctuations also did not differ largely between the different micelle sizes except for strongly reduced fluctuations of HL1 in the larger micelle (**Figure 6 – figure supplement 3F**) originating from the more ordered DDM molecules around HL1 (**Figure 6 – figure supplement 3H**). Furthermore, TMD6a and residues C-terminal of TMD6a were found to be also flexible in the larger DDM micelle as observed for the smaller micelle (**Figure 6 – figure supplement 3F, G**), indicating that the size of

the DDM micelle does not influence the observed differences in flexibility of TMD6a between DDM and POPC environment.

Although most of the DDM molecules are well aligned to the membrane normal at the protein periphery, some can transiently flip to a direction perpendicular to the membrane normal near to the gaps between TMDs (such as TMD2-TMD6 and TMD3-TMD4) (**Figure 6B-D, Video 1 and Video 2**). When inserted into the intramolecular gaps between TMD2 and TMD6, the DDM molecule perturbs intramolecular interactions by forming unspecific hydrogen bonds with the adjacent amino acid backbones, and thus destabilizes TMD6a (**Figure 6B-C**). In addition, DDM inserts between TMD3 and TMD4 of PSH in the micelle environment and interacts with the loop C-terminal of TMD6a, corresponding to the higher RMSF observed for these residues (**Figure 5E, Figure 6D**). In contrast, the well-ordered POPC molecules do not enter into the gaps between TMDs (**Video 3**) and do, therefore, not disturb intramolecular interactions. Collectively, these data suggest that a membrane lipid environment promotes the formation of a stabilized E-S of PSH with the APP C83 substrate by the stabilization of TMD6a, an important structural element involved in substrate stabilization.

Lysine mutations in TMD6a lead to helix unwinding and reduced activity

Our computational results suggest that the TMD6a helix plays an important role for substrate binding of PSH. Furthermore, the residues of the hydrophobic patch in TMD6a (M172, I173, L175 and A176) of PSH correspond to a homologous hydrophobic patch in the TMD6a of PS1 (L271, V272, T274 and A275), which is also affected by FAD mutations³. Some of them display a strong loss of function such as L271V and T274R⁴⁰ supporting the idea that TMD6a has an important function in substrate cleavage. To investigate the functional role that TMD6a plays in substrate

stabilization, we performed additional MD simulations of *in silico* generated lysine mutations of M172, I173, L175 and A176 in the TMD6a hydrophobic patch in order to disrupt its nonpolar character. Because TMD6a is already unstable in DDM, the simulations were performed in the POPC environment only. The RMSD plots indicate that in most of the simulations, mutated PSH remained in an overall stable structure with RMSDs ~ 3.0 Å (similar to WT) (**Figure 7A**). In addition, no significant difference was found in C83 RMSF (**Figure 7B**), residue-wise water distribution (**Figure 7C**) and the hydrogen-bonding pattern of the β -sheet C-terminal of the ϵ -cleavage site (**Figure 7D**).

The PSH RMSF plots show that all mutations destabilize TMD6a to different degrees while having only smaller effects in other regions in comparison to WT (**Figure 7E**). It is worth noting that L175K introduces the largest TMD6a fluctuation, compared to the WT and the other three lysine mutants. Nevertheless, all four mutations distorted the helical structure of TMD6a in at least one of the simulations. (**Figure 7 – figure supplement 1**). Finally, to experimentally validate these structural predictions, we analyzed the cleavage of C99 by these mutant forms of PSH. All four mutants showed a strongly decreased, nearly abolished cleavage of C99 compared to WT PSH in both DDM micelle or POPC bilayer conditions (**Figure 7F**) suggesting that TMD6a and its hydrophobic patch is an important structural element of PSH.

Lipid membrane environment stabilizes the active site geometry of PSH

The proteolysis reaction requires a specific geometry of all elements that form the active site. A critical issue is the distance between the two catalytic aspartic acids D162 and D220. Free energy calculation along the distance between D257 and D385 of PS1 has suggested that mutations disturbing the active site geometry and

alter the distance between D257 and D385 correlate with changes in enzyme activity⁴¹. In PSH, the geometry is characterized by the Cy-Cy distances between the D162 and D220. The distances appeared more frequently around 6.8 Å in our model when placed in a bilayer environment (**Figure 8A, Figure 8 – figure supplement 1**). These distances correspond to a potentially catalytically active site geometry that can also accommodate a water molecule between the catalytic aspartates and L49 essential for the proteolytic cleavage (**Figure 8B**). In contrast, larger distances are more frequently sampled in the micelle environment. When the distance is enlarged here, an increased number of water molecules can access the catalytic center and disturb the catalytic geometry (**Figure 8B**). Proteolysis-compatible Cy-Cy distances below 7.0 Å were more frequently sampled in the membrane environment (~ 76%) compared to simulations in the DDM environment (~ 63%). Detailed geometries at the catalytic site of the E-S for a smaller and a larger Cy-Cy distance are depicted in **Figure 8 – figure supplement 2A, B**.

To experimentally test whether the lipid environment influences the active site geometry of PSH, we used the L-685,458-based biotinylated affinity ligand Merck C⁴² to capture PSH in DDM micelles and in POPC vesicles. As shown in **Figure 8C**, Merck C was able to capture specifically PSH as judged from binding competition in the presence of excess amounts of the parental compound L-685,458. In all these experiments, binding competition was stronger in the POPC vesicles than in DDM micelles indicating that the more labile DDM environment also weakens the competition of binding with the parental compound. In addition, also the background level of unspecific binding was higher in the latter environment contributing to the higher levels of unspecific PSH capture. In agreement with these observations, quantitation of specifically Merck C-bound PSH showed that the capture was markedly enhanced for the protease in the POPC bilayer (**Figure 8D**). Additional

enzyme inhibition experiments further showed that both inhibitors, the parental L-685,458 as well as Merck C, inhibited PSH less well in DDM than in POPC (**Figure 8E, F**). All in all, these findings support the interpretation that the POPC bilayer stabilizes the active site, whereas it is destabilized in DDM micelles. Thus, these data suggest that the lipid environment stabilizes the geometry of the active site, which translates into the increased processivity of PSH in POPC vesicles.

Despite the improved binding and capture of PSH by the L-685,458-derived affinity probe in the POPC membrane environment, a potent inhibition of PSH by L-685,458 required rather high micromolar concentrations of this GSI. We thus finally tested whether other known GSIs would be more effective in inhibiting PSH cleavage of C99. Besides L-685,458, another TSA inhibitor (III-31C⁴³, **Figure 8 – figure supplement 3A, B**) and four non-TSA inhibitors with comparable potency (DAPT⁴⁴, LY411575⁴⁵, Begacestat⁴⁶ and MRK-560⁴⁷, **Figure 8 – figure supplement 3C-F**) were tested for their potential to inhibit reconstituted PSH at pH 7.0. Remarkably, only the TSA inhibitor III-31C was able to inhibit C99 cleavage by PSH whereas the non-TSA inhibitors were largely ineffective, even when used at the same high concentrations as for L-685,458 (20 μ M) (**Figure 8G**). Overall, these inhibition data suggest that the stabilizing interactions of the TSA inhibitors in the PSH active site region may be different from that of γ -secretase^{29,48}. Such differences in stabilizing interactions might also affect the other GSIs that may bind too weakly to inhibit the enzyme.

Taken together, the MD simulations indicate a more stable, i.e. less fluctuating, geometry of the enzyme-substrate binding state around the enzyme active site in a POPC membrane environment compared to a DDM micelle environment. The DDM environment appears to destabilize important structural elements such as the TMD6a that is required for a stable enzyme-substrate interaction. These results can

qualitatively explain the experimentally observed reduced processivity of PSH in DDM micelles and its boost in the POPC bilayer. Further, they emphasize the critical importance of the membrane environment for the formation of a conformationally stable active site geometry in the E-S complex, which is key for the efficient operation of intramembrane proteases in general.

DISCUSSION

It has previously been demonstrated that the archaeal intramembrane protease PSH cleaves the APP substrate C99 into A β 40 and A β 42 in a manner very similar to γ -secretase¹⁶. PSH can thus be used as a surrogate for γ -secretase allowing to study the proteolytic activity of its catalytic presenilin subunit in the absence of its complex partners. Here we confirm and extend these prior findings by a further, more in depth characterization of C99 processing by PSH. We first found that detergent-solubilized PSH cleaves C99 in DDM micelles with a reduced processivity as evident from higher amounts of A β 42 than A β 40. The reduced processivity of PSH under these conditions was supported by the identification of longer A β species such as A β 46, cleavage products that were not identified in the previous study. Strikingly, we found in our assay system that the processivity was strongly enhanced in a membrane bilayer when the enzyme was reconstituted into POPC SUVs. Under these conditions, PSH processivity was strongly promoted as seen by the increased production of A β 38. The protease was pH-dependent and showed the highest activity in the mild acidic to mild alkaline pH range in both micelle and bilayer conditions. In the POPC bilayer, the processivity of PSH was increased up to neutral pH before it rapidly dropped in the alkaline pH range of 7.5 – 8.5, where longer A β species started to accumulate eventually remaining unprocessed. Although the pH/activity profile of PSH showed overall similarities to that of γ -secretase, there

were some notable differences. Compared to γ -secretase, which has a pH optimum of 6.5³⁷, that of PSH was shifted to neutral pH. Moreover, although the processivity of γ -secretase was increasingly impaired towards more alkaline conditions like for PSH shown here, paradoxically, relative increases of A β 38 were observed for γ -secretase in parallel³⁷. Clearly, the most remarkable observation, however, was the rise in processivity when PSH was reconstituted into POPC membranes.

In searching for the underlying basis of these dramatic activity changes when changing from a micelle to a bilayer environment, we asked if these could be due to potential structural rearrangements that PSH undergoes in these two different environments. To investigate this possibility, PS1-based homology models were generated for PSH in the APP C83 substrate-bound holo form and the substrate-free apo form. The models revealed both β 2-strand and TMD6a as structural elements, which we found by mutational analysis to be functionally highly critical for substrate cleavage by PSH. As observed for substrate-bound PS1^{26,27}, this suggests that they constitute important structural elements for substrate binding also for PSH.

The conformational dynamics of these structural models was evaluated in MD simulations to test whether structural changes might be observable that could explain the activity changes. We note that in previous simulations the atomistic dynamics of γ -secretase and the interaction with C83 have been studied^{49,50}, including very recently also its activated state poised for ϵ -site cleavage⁵⁰. However, comparative simulations in detergent micelles and lipid bilayer have so far not been performed. Among three models, model 2 is considered as the most realistic model and was chosen as working model for the E-S in our study. Our simulation results on PSH clearly showed more structural fluctuations of the protease in the micelle environment than in the membrane environment. These translated into less stable interactions with the substrate in the micelle compared to that in the bilayer, particularly of TMD6a

with C83 in the active site region. In line with our mutational analysis, changing residues within the hydrophobic patch of TMD6a, which interacts with residues V50 and L52 at or near, respectively, the ϵ 49-site of the substrate, disrupted interactions with the substrate in the MD simulations and strongly interfered with substrate cleavage in the PSH cleavage assays thus linking functional biochemical data with structural dynamics of PSH. TMD6a thus further emerges as an important structural element for substrate interaction that appears to be able to sense changes in the hydrophobic environment of the protease. The increased stability of TMD6a in POPC reflects a stabilized enzyme-substrate interaction that could likely translate into the enhanced processivity observed for the membrane environment. A more stable interaction increases the substrate residence time at the enzyme that has been shown for γ -secretase to be key for its processivity⁵¹ and that is also supported by MD simulations of a γ -secretase–C99 complex⁵². Moreover, a closer distance of the catalytic aspartate residues was much more frequently observed for the substrate-bound PSH holo form in the POPC bilayer suggesting that the formation of an active site geometry capable of peptide bond hydrolysis is promoted in the membrane environment. Consistent with these data, we found that binding of PSH to Merck C, a biotinylated derivative of L-685,458, was increased in the POPC bilayer. As shown previously for γ -secretase, L-685,458 interacts with the same subsite pockets as C83 and occupies a position of the substrate in the active site region close to where also the ϵ -cleavage sites of C83 become exposed and are unfolded^{29,48}.

Despite the demonstration of direct binding of the L-685,458 lead structure to PSH using the Merck C affinity ligand, L-685,458 inhibited PSH much less efficiently than γ -secretase, i.e. micromolar concentrations were needed to inhibit PSH compared to nanomolar concentrations known to inhibit γ -secretase. Likewise, and consistent with previous results¹⁶, the related TSA inhibitor III-31C could inhibit C99

cleavage of PSH but again at micromolar concentrations. Since other non-TSA GSIs failed to inhibit PSH, only TSA inhibitors can interact with PSH and effectively inhibit the enzyme. This suggests that the binding sites for non-TSA GSIs are different or, more likely, that their interactions with PSH are too weak to inhibit the enzyme. As shown previously, the binding sites of the non-TSA GSIs Avagacestat and Semagacestat are similar to the binding site of the TSA GSI L-685,458²⁹. The non-TSA GSIs occupy the position of the β -strand of the substrate but do not protrude to the catalytic site resulting in decreased interactions with γ -secretase compared to the TSA GSI²⁹.

Both our experimental studies and the corresponding comparative MD simulations therefore suggest that the higher conformational flexibility of PSH in micelles causes destabilized interaction with C83 and C99 and consequently a reduced processivity. In contrast, a lipid bilayer induces a less flexible conformation of PSH that allows a more stable interaction with substrate, thereby promoting the processivity of PSH. Our data support recent findings for γ -secretase that showed differences in the processivity in micelles and a lipid raft-like membrane environment⁵³ and now provide an underlying molecular basis for this behavior. Similar to an artificial destabilization of the PSH/presenilin fold in detergent micelles, computational analyses suggest that FAD mutations in presenilin cause structural destabilizations^{41,54,55} which are consistent with the experimentally observed impact on substrate interactions of these mutants^{56,57} and their alteration of APP/A β E-S stabilities resulting in processivity impairments⁵³. We also note that a less stable E-S in detergent micelles might account for differences in cleavage site usage and in inhibition profiles for diverse C99-based substrates that were observed in previous PSH assays^{15,16,18}.

Presumably, due to their non-native environment, the available structures of GxGD-type proteases show catalytically inactive conformations with too distant catalytic residues. The large distance of the catalytic aspartates of PSH in the substrate-free apo form is also seen for γ -secretase (10.6 Å,²⁵) as well as in different GxGD-type aspartyl proteases like FlaK (12 Å,⁵⁸) and seems to represent their inactive form. Upon substrate interaction, this distance is decreased bringing the two catalytic aspartates closer to the initial cleavage sites^{26,27}. As now shown in our study, a lipid bilayer environment promotes the formation of a stable active-site geometry by bringing the catalytic residues, water and the substrate scissile bonds into a conformation that allows proteolysis to proceed more efficiently. As a general implication for intramembrane proteolysis, our data suggest that a lipid bilayer-mediated stabilization of the active-site geometry might also be observable for other intramembrane proteases of different catalytic types.

Taken together, to our knowledge, this is the first extensive study of the influence of micelle and membrane environment on intramembrane cleavage at the level of enzyme activity and E-S structural dynamics. In good correlation between experimental and simulation data, our results with PSH as a model intramembrane protease highlight a previously not recognized important role of the membrane-lipid environment in providing a stabilized E-S conformation that is crucial for substrate processing in intramembrane proteolysis. Our data further underscore a key role of the conformational flexibility of presenilin/PSH TMD6a for substrate interactions and proteolytic cleavage of presenilin-type proteases. Most importantly, they provide evidence that the lipid bilayer promotes the formation of a conformationally stable active site geometry, which is of general importance for an efficient catalytic operation of intramembrane proteases.

MATERIALS AND METHODS

Antibodies

Monoclonal antibody 6F4 (IgG2b/k) to PSH was raised in Wistar rat against amino acid residues 192-204 (KRADYSFRKEGLN) of PSH from *Methanoculleus marisnigri* (immunoblot (IB): 3 µg/ml). Monoclonal antibody 2D8 to Aβ1-16 was described previously⁵⁹ (IB: 3 µg/ml). Polyclonal antibody 6687 against APP-CTF was described previously⁸ (immunoprecipitation (IP): 1:100–1:200). Polyclonal antibody Anti-β-Amyloid (22-35) to Aβ22-35 (Sigma-Aldrich, A3356, IB: 1:1000) and monoclonal antibodies 4G8 to Aβ17-24 (BioLegend, 800702, IP: 1:500–1:2,500), Penta-His Antibody (Qiagen, 34660, IB: 1:1000) and Y188 to APP C-terminus (Abcam, ab32136, IB: 1:5000) were purchased from the indicated suppliers.

PSH constructs

All constructs are based on the PSH expression construct in pET-21b used for structure determination²³. PSH point mutations and deletion were generated using site-directed mutagenesis. DNA sequencing of the newly generated plasmid confirmed successful mutagenesis.

PSH expression and purification

Expression and purification of WT and mutant PSH was adopted from the published protocol²³. In brief, *E. coli* BL21(DE3) cells transformed with the pET-21b vector harboring an N-terminal 8x His-tagged PSH were grown in LB medium to an optical density of 1.5 and expression was induced with 0.2 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). PSH was expressed at 22 °C overnight and harvested cells were resuspended in resuspension buffer (25 mM Tris-HCl, pH 8.0, 150 mM NaCl). Cells were lysed by sonication; cell debris was removed by centrifugation and

membranes were collected by ultracentrifugation at 150,000 x *g* for 1 h. Membranes were solubilized in resuspension buffer containing 2% DDM by rocking at 4 °C for 2 h. After ultracentrifugation at 150,000 x *g* for 30 min, the supernatant was incubated with Ni-NTA agarose beads (Qiagen) for 2 h at room temperature. Beads were then washed with resuspension buffer containing 20 mM imidazole and 0.6% (w/v) DDM. PSH was eluted with resuspension buffer containing 250 mM imidazole and 0.6% (w/v) DDM.

PSH reconstitution in POPC vesicles

PSH reconstitution into POPC SUVs was based on the reconstitution of γ -secretase into SUVs³⁶. SUVs were prepared in a low citrate buffer (5 mM sodium citrate, 3.5% glycerol, pH 6.4) and diluted 2.5 times with buffer (5 mM sodium citrate, 3.5% glycerol, 30 mM DTT, pH 6.4). One volume of purified PSH and four volumes of the vesicle preparation were mixed in the presence of an excess of Calbiosorb adsorbent beads (Calbiochem) and incubated at 4 °C overnight to allow the formation of proteoliposomes.

Validation of PSH reconstitution into POPC SUVs

To validate the incorporation of PSH into POPC vesicles, PSH was reconstituted into POPC vesicles containing the fluorescent marker lipid rhodamine-DHPE. These vesicles were then subjected to a small gel filtration column packed with Sephacryl S200 HR to separate vesicles and free PSH. The vesicle content of each fraction was analyzed by measuring fluorescence (λ_{ex} 530 nm, λ_{em} 590 nm) with Fluoroscanner Asket FI (Labsystems) and the presence of PSH in the fractions was analyzed by immunoblotting with antibody 6F4.

APP substrate constructs

Recombinant APP substrate C100-His₆ was described before²¹. The corresponding C83-His₆ (containing an N-terminal methionine) was generated by PCR and cloned into pQE60.

Expression and purification of APP-based substrates

C100-His₆ and C83-His₆ were expressed in *E. coli* BL21(DE3)_{RIL} cells after induction with IPTG at 37 °C for 4 h. Cell pellets were resuspended in TE buffer (20 mM Tris (pH 7.5), 1 mM EDTA), sonified and inclusion bodies were collected by centrifugation. Inclusion bodies were lysed overnight at 4 °C in 20 mM Tris (pH 8.5), 6 M urea, 1 mM CaCl₂, 100 mM NaCl, 1% (w/v) SDS and 1% (v/v) Triton X-100 by rotation. The lysate was diluted 1:5 with 20 mM Tris (pH 7.5) and 150 mM NaCl and then incubated with Ni-NTA agarose for 2 h at room temperature. Ni-NTA beads were washed extensively with TX-wash buffer (50 mM Tris (pH 8.5), 300 mM NaCl, 1% (v/v) Triton X-100), SDS-wash buffer (50 mM Tris (pH 8.5), 300 mM NaCl, 0.2% (w/v) SDS) and imidazole wash buffer (50 mM Tris (pH 8.5), 300 mM NaCl, 0.2% (w/v) SDS, 20 mM imidazole) before the elution of bound protein with elution buffer (50 mM Tris (pH 8.5), 300 mM NaCl, 0.2% (w/v) SDS, 150 mM imidazole).

PSH *in vitro* assay

The *in vitro* assays using recombinant APP substrates C100-His₆ and C83-His₆ was performed with either DDM-solubilized PSH or reconstituted PSH. To test PSH activity over a range of different pH values, the *in vitro* assay was performed in the presence of a master buffer (20 mM Bicine, 20 mM HEPES, 20 mM MES) adjusted to different pH values (pH 5.5 to 9.0). 1 - 2 μM PSH was incubated with 0.5 μM substrate overnight at 37 °C. The final DDM concentration was 0.02% for the assays

in DDM micelles. For the assays with PSH reconstituted in POPC vesicles a small amount of DDM was added just below the critical micelle concentration (CMC) of 0.0087%. Generated AICD, A β and p3 were analyzed by immunoblotting and in addition, A β and AICD species were determined by MALDI-TOF mass spectrometry (MS) analysis as described previously⁶⁰⁻⁶². In brief, samples were diluted with IP-MS buffer (10 mM Tris (pH 8.0), 140 mM NaCl, 0.5 mM EDTA, 0.1% n-octyl-glucopyranoside) and immunoprecipitated for 16 h at 4 °C with antibody 4G8 and protein G-Sepharose for A β species or with antibody 6687 and protein A-Sepharose for AICD species.

Electrochemiluminescence immunoassay (ECL-IA)

A β and p3 species from PSH *in vitro* assays were analyzed with the V-PLEX Plus A β Peptide Panel 1 (4G8) Kit (Meso Scale Discovery, K15199G) using SULFO-tagged anti-A β antibody (4G8) in a 1:50 dilution. Samples were centrifuged for 30 min at 21,000 x *g* and then diluted 1:25 to reach a sample concentration in the linear detection range. The ECL-IA was performed following the manufacturer's protocol.

Inhibitor affinity precipitations of PSH

Streptavidin Sepharose beads (GE Healthcare) were washed three times with PBS and then blocked overnight with 1% I-Block in PBS at 4 °C and additionally for 30 min at room temperature. PSH in DDM micelles or in POPC vesicles was diluted with MES-buffer (50 mM MES pH 6.0, 500 mM NaCl, 5 mM MgCl₂, 1x PI mix complete (Roche)) to 1 - 2 μ M PSH. To mimic the cleavage assay condition, a small amount of DDM was added just below the CMC of DDM (0.0087%) to the POPC reconstituted PSH. The diluted PSH solution was precleared with streptavidin beads for 30 min at 4 °C. To capture PSH, the precleared solution was incubated with L-685,458-based

biotinylated TSA inhibitor Merck C⁴² (Taros Chemicals) in the presence of streptavidin beads for 2 h at room temperature. To analyze non-specific binding, Merck C was omitted or a 100-fold molar excess of the parental compound L-685,458 was added. To quantify Merck C GSI binding to PSH, the chemiluminescence signal of the respective immunoblots were quantified using the LAS-4000 image reader (Fujifilm Life Science) and GelAnalyzer 19.1 software (www.gelanalyzer.com). Specific binding was calculated as the difference between the binding of PSH and the binding of PSH in presence of the competitor L-685,458 after subtraction of unspecific PSH binding to the beads.

Molecular dynamics simulations

The available crystal structures of PSH, PDB 4HYG²³ and PDB 4Y6K¹⁶ include several amino acid substitutions compared to the WT PSH sequence and in addition, several important loop segments are missing. In both crystals, the enzyme forms a tetramer that may also stabilize a structure different from the solution and substrate-bound conformation. Under the assumption that a substrate is bound to PSH in an analogous fashion as in the PS1 homolog, we used the option to generate a comparative model structure using the C83 substrate-bound γ -secretase structure (PDB 6IYC)²⁶ as a template. Three models were generated using the SWISS online server⁶³ and the program MODELLER⁶⁴ with a same sequence alignment strategy (**Figure 4 – figure supplement 2**) but different homology protocols. Model 1 was built by taking only PDB 6IYC as the template as generated by the SWISS online server (**Table 1**). Model 2 was generated by using residues ranging from L7 to D162 and D220 to L292 from chain B of PDB 4HYG and model 1 as templates with the MODELLER multi-template method (**Table 1**). Model 3 was built by taking all residues resolved in chain B of PDB 4HYG and model 1 with the MODELLER multi-

template method (**Table 1**). Similar to the PS1 template structure, the final holo PSH structure is composed of two fragments with an N-terminal fragment from L7-R193 and a C-terminal fragment from E210 to A293. The generated holo-state PSH structures were then embedded in two different environments: micelle capsules consisting of 150 DDM molecules and a membrane bilayer with 302 POPC molecules. An additional, larger micelle capsule system of model 2 was constructed with 50% more, namely 225, DDM, molecules. Lysine mutations M172K, I173K, L175K and A176K were constructed based on model 2 with RMSD (WT vs mutant) < 0.1 Å, and embedded in a membrane bilayer system with 302 POPC molecules using the CHARMM-GUI online server. All 11 systems were prepared and solvated in explicit TIP3P water⁶⁵ at a salt concentration of 0.15 M KCl using the CHARMM-GUI online server.^{66,67}

The interaction of proteins, lipid and micelles is described by the charmm36m force field⁶⁸. Each system was simulated using the AMBER18 pmemd GPU accelerated version⁶⁹ in combination with a Berendsen barostat (1 bar) and a Langevin thermostat (303.15 K). The hydrogen mass repartitioning method was used allowing a time step of 4 fs. Three simulations with 600 ns each were performed for each system, in total 33 NPT trajectories were generated for further analysis. Non-bonded cutoff was set to 12 Å with a force-based switching distance of 10 Å. D220 was selected to be protonated while D162 was unprotonated according to the pK_a prediction on the existing PSH and PS1 structures by PROPKA3.1⁷⁰ (**Table 2**).

The lipid tail order parameter S_{CH} was computed in model 2 in DDM and POPC environments to show the orientation and the ordering of the concerning CH vector^{71,72} with respect to the protein principle axis, which was aligned to the lipid

normal in the POPC environment. In addition, the area per lipid was computed in model 2 on both leaflets to verify the reliability of our POPC lipid model.

RMSF of PSH and C83 curves were calculated by taking the last 200 ns with the time-average PSH structure of each simulation as the reference and only taking the backbone atoms for the calculation. Secondary structure of PSH TMD6a was calculated using the DSSP method⁷³.

ACKNOWLEDGEMENTS

This work was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation – 263531414 / FOR2290; M.Z. and H.S.). We thank Yigong Shi for the PSH expression plasmid, Karlheinz Baumann for GSIs and Gabriele Basset, Frits Kamp and Alice Sülzen for technical assistance.

COMPETING INTERESTS

The authors declare no competing interests.

FIGURE LEGENDS

Figure 1. Cleavage of APP C99 by PSH.

(A) Schematic illustration of APP C99 cleavage by PSH. PSH cleaves C99 and releases an AICD fragment and A β peptides. The epitope of the PSH specific antibody 6F4 in the loop between TMD6 and TMD7 is indicated.

(B) Analysis of PSH activity in DDM micelles after incubation with C100-His₆ substrate overnight at 37 °C by immunoblotting for AICD (Y188) and A β (2D8). Specificity of substrate cleavage by PSH in the assay was controlled by sample

incubation at 4 °C or 37 °C in presence of the GSI L-685,458 (20 µM).
Immunoblotting of PSH (6F4) was performed to control for PSH levels.

(C) Aliquot of samples from (B) separated by Tris-Bicine urea SDS-PAGE for identifying Aβ species produced by PSH in DDM micelles and analysis by immunoblotting (2D8). In (B) and (C), representative immunoblots from 3 to 6 independent biological replicates (i.e. independent protease preparations) are shown.
(D) Representative MALDI-TOF MS spectrum of Aβ profile generated by PSH in DDM micelles from 4 independent biological replicates. The intensity of the highest peak was set to 100%. A GSI control is shown in **Figure 1 – figure supplement 1** and observed masses for identified Aβ species are shown in **Figure 1 – source data 1**.

Figure 2. Comparison of PSH cleavage activity and processivity in DDM micelles and POPC bilayer.

(A) Analysis of PSH activity in DDM micelles and POPC vesicles after incubation with C100-His₆ substrate at 37 °C overnight by immunoblotting for AICD (Y188) and Aβ (2D8). Immunoblotting of PSH (6F4) was performed to control for PSH levels.

(B) Separation of Aβ species produced by PSH in DDM micelles and POPC vesicles by Tris-Bicine urea SDS-PAGE and analysis by immunoblotting for Aβ (2D8). In (A) and (B), representative immunoblots from 6 independent biological replicates are shown. Confirmation of PSH reconstitution in POPC SUVs is shown in **Figure 2 – figure supplement 1**.

(C, D) MALDI-TOF MS analysis of Aβ (C) and AICD (D) species generated by PSH in DDM micelles and POPC vesicles at pH 7.0. Representative mass spectra from 4 independent biological replicates are shown. The intensity of the highest peak was set to 100%. GSI controls are shown in **Figure 2 – figure supplement 2** and

observed masses for identified A β and AICD species are shown in **Figure 2 – source data 1**.

Figure 3. Cleavage of APP C83 by PSH.

(A) Analysis of PSH activity in DDM and POPC environment after incubation with C83-His₆ and C100-His₆ substrates at 37 °C and pH 7.0 by immunoblotting for AICD (penta-His) and p3 (A β (22-35)). Immunoblotting of PSH (6F4) was performed to control for PSH levels.

(B, C) p3-40/p3-42 ratio (B) and A β 40/A β 42 ratio (C) from PSH activity assays in DDM (red) and POPC (blue) environment analyzed by ECL-IA. Quantitative data are represented as mean $\pm$ standard deviation (SD) (n = 3 biological replicates). Source data are shown in **Figure 3 – source data 1**.

Figure 4. PSH homology model.

(A) Alignment of the modeled holo form (model 2) of PSH (blue) with APP C83 substrate (orange) and the crystal structure of PSH (PDB 4HYG) in the apo form (green) in side view (left panel) and top view (right panel). An overlay of all three models and their RMSD values are provided in **Figure 4 – figure supplement 1A and B**.

(B) Schematic representation of the hydrogen bonds formed between β 3 of the substrate (orange), β 2, and Q272, respectively, of PSH (blue).

(C) Interaction of TMD3 and TMD6a in the C83-bound PSH model through residues R70 and E181.

(D) Interaction of TMD3 and TMD6a through residues Y159 and R278 in the C83-bound γ -secretase cryo-EM structure (PDB 6IYC).

(E) Analysis of WT and mutant PSH activity in DDM and POPC environment after incubation with C100-His₆ substrate at 37 °C overnight by immunoblotting for AICD (Y188) and Aβ (2D8). Immunoblotting of PSH (6F4) was performed to control for PSH levels. The asterisks mark two substrate degradation bands, which are independent of PSH cleavage.

Figure 5. MD simulations of holo PSH forms in DDM micelle or POPC bilayer.

(A) PSH with bound C83 substrate (model 2) embedded in a DDM micelle environment (upper panel) and a POPC bilayer (lower panel).

(B) The average number of H-bonds formed between the β3-strand of C83 and the β2-strand of PSH. Each data point stands for the average value throughout one trajectory and the error bars represent the SD of the mean of three data points.

(C) The backbone RMSF of C83 of different models in DDM (red) and POPC (blue) environments averaged over three trajectories. The shaded areas represent the SD of the mean.

(D) Water accessibility along the substrate TMD residues extracted from the simulations of the holo PSH in DDM (red) and POPC (blue) environments (water accessibility for a residue is obtained as the mean number of water molecules within 5 Å of any atom of the residue). The red arrows indicate the position of the two ε-cleavage sites. The error bars represent the SD of the mean (n = 3 trajectories).

(E) The backbone RMSF of PSH of different models in DDM (red) and POPC (blue), environments averaged over three trajectories. The gray boxes highlight TMD6a and the shaded areas represent the SD of the mean. Enlarged views on backbone RMSF of residues K170 to P185 (including TMD6a) are shown in **Figure 5 – figure supplement 1B**.

Figure 6. Destabilization of PSH TMD6a in a DDM micelle.

(A) Hydrophobic interactions between PSH regions and the C83 substrate. The right panel shows an enlarged view of the interaction of a hydrophobic patch (gray surface) of TMD6a with V50 and L52 of the substrate in the POPC bilayer.

(B, C) Snapshots of the DDM insertion between TMD2 and TMD6 in the first (B) and second (C) run of the simulations in DDM environment at 400 ns. The right panels show an enlarged view of the unspecific hydrogen bonding interactions between the DDM molecule and the TMD6a amino acid backbones.

(D) Snapshot of the DDM insertion between TMD3 and TMD4 of the simulation in DDM environment at 430 ns. The right panel shows an enlarged view of the unspecific hydrogen bonding interactions between the DDM molecule and the amino acid backbones of the residues immediately C-terminal of TMD6a.

Figure 7. Impact of PSH TMD6a mutations on PSH structural dynamics and activity.

(A) RMSD of the WT (blue) and the mutated systems M172K (violet), I173K (green), L175K (gray), and A176K (orange) in the POPC bilayer environment. The solid, dashed, and dotted lines represent three different simulations with random initial velocities. The black dashed line indicates an RMSD of 4 Å.

(B) The backbone RMSF of C83 of WT PSH and different TMD6a lysine mutants in POPC environment averaged over three trajectories. The shaded areas represent the SD of the mean.

(C) Water accessibility along the substrate TMD residues extracted from the simulations of the four lysine-mutant holo-form PSH systems in the POPC bilayer environments (water accessibility for a residue is obtained as the mean number of water molecules within 5 Å of any atom of the residue). The red arrows indicate the

position the two ϵ -cleavage sites. The error bars represent the SD of the mean ($n = 3$ trajectories).

(D) The average H-bond formed between the β 3-strand at the C-terminus of C83 and the β 2-strand of WT and lysine-mutated PSH. Each data point stands for the average value throughout one trajectory and the error bars represent the SD of the mean of three data points.

(E) The backbone RMSF of WT (blue) and M172K (violet), I173K (green), L175K (gray), and A176K (orange) mutated PSH in POPC. The box highlights TMD6a and the shaded areas represent the SD of the mean ($n = 3$ trajectories).

(F) Analysis of WT and lysine-mutant PSH activity in DDM and POPC environment after incubation with C100-His₆ substrate at 37 °C overnight by immunoblotting for AICD (Y188) and A β (2D8). Immunoblotting of PSH (6F4) was performed to control for PSH levels. The asterisks marks substrate degradation bands, which are independent of PSH cleavage.

Figure 8. Stabilization of the PSH active site geometry in a POPC bilayer.

(A) Histograms of the Cy-Cy distances between the D162 and D220 of PSH measured in DDM micelle (red) and POPC bilayer (blue) environments. The dashed line indicates the distance of 7 Å. The measured distances over time are shown in

Figure 8 – figure supplement 1C.

(B) Snapshot of the catalytic cavity in DDM (left panel) and POPC (right panel) environment. The Cy-Cy distance between the two catalytic aspartates D162 and D220 is larger in DDM micelles and more water molecules enter the catalytic cavity between D162 and the substrate. Detailed geometries of these two active site conformations are depicted in **Figure 8 – figure supplement figure 2.**

(C) Immunoblot analysis of TSA-inhibitor binding to PSH in DDM micelles or POPC vesicles. PSH was affinity-precipitated by Merck C (a biotinylated derivative of L-685,458; 20 μ M). To control for background binding and binding specificity, the affinity precipitation was assessed in the absence of Merck C as well as in the presence of excess amounts of the parental compound L-685,458 (2 mM) as competitor. The input represents 2.5% of the total sample used for the affinity precipitation. A representative immunoblot from 4 independent biological replicates is shown.

(D) Quantitation of PSH binding by Merck C. Specific binding was defined as difference of PSH signals in the absence or presence of L-685,458 after additional subtraction of unspecific background binding signals. Quantitative data are represented as mean $\pm$ SD (n = 4 biological replicates). The source data are shown in **Figure 8 – source data 1**.

(E, F) Inhibition assay of PSH in DDM micelles and POPC vesicles with increasing concentrations of L-685,458 (E) or Merck C (F), respectively. PSH activity was analyzed by immunoblotting for AICD (Y188) and A β (2D8) following incubation with C100-His₆ substrate at 37 °C overnight. Representative immunoblots from 3 independent biological replicates are shown. The asterisks mark two substrate degradation bands, which are independent of PSH cleavage.

(G) Inhibition assay of PSH reconstituted in POPC vesicles in the presence of 20 μ M TSA and non-TSA γ -secretase inhibitors. PSH activity was analyzed by immunoblotting for AICD (Y188) and A β (2D8) following incubation with C100-His₆ substrate at 37 °C overnight. Representative immunoblots from 3 independent biological replicates are shown.

TABLES

Table 1. Templates used for model building of PSH in complex with C83. Residues of PSH used for model building are indicated.

Table 2. pK_a predictions as calculated by PROPKA3.1 for published PSH and γ -secretase structures. pK_a values of the catalytic aspartate residue which is most likely protonated are indicated in red.

FIGURE SUPPLEMENTS

Figure 1 – figure supplement 1. MS specificity control for A β cleavage products generated from APP C99 by PSH.

Representative MALDI-TOF MS spectrum of PSH cleavage assay in DDM micelles in the presence of L-685,458 from 4 independent biological replicates. The intensity of the highest peak was set to 100%.

Figure 2 – figure supplement 1. Reconstitution of PSH in POPC vesicles.

(A) Fluorometric analysis of gel filtration fractions of PSH-containing POPC vesicles with rhodamine-DHPE as fluorescent marker lipid. A representative graph from 3 independent biological replicates is shown.

(B) Analysis of gel filtration fractions by immunoblotting for PSH (6F4). A representative immunoblot from 3 independent biological replicates is shown.

Figure 2 – figure supplement 2. MS specificity controls for A β and AICD cleavage products generated from APP C99 by PSH.

(A, B) MALDI-TOF MS analysis of A β (A) and AICD (B) species from PSH cleavage assays in DDM micelles and POPC vesicles in the presence of L-685-458 at pH 7.0.

Representative mass spectra from 4 independent biological replicates are shown.
The intensity of the highest peak was set to 100%.

Figure 4 – figure supplement 1. Comparison of the three different homology models.
(A) Alignment of the three modeled holo forms of PSH in side view (left panel) and top view (right panel).
(B) RMSD values between the available crystal structures (PDB 4HYG and 4Y6K) and the three different PSH models.

Figure 4 – figure supplement 2. Alignment of PS1 and PSH used for homology modelling based on the TMD annotations of the available cryo-EM or crystal structures, respectively (PDB 6IYC for PS1 and PDB 4HYG for PSH). Active site motifs including the catalytic aspartate residues (red) are highlighted in bold.

Figure 5 – figure supplement 1. Homology modelling of the holo form PSH in complex with C83 in DDM and POPC environments.

(A) The backbone RMSD of PSH of different models in DDM (red) and POPC (blue) averaged over three trajectories. The black dashed line indicates an RMSD of 4 Å.

(B) Enlarged representation of backbone RMSF of residues K170 to P185 (including TMD6a (orange)) of different models in DDM (red) and POPC (blue) environments averaged over three trajectories. The shaded areas represent the SD of the mean and the black dashed lines indicate an RMSD of 1 Å.

Figure 5 – figure supplement 2. Secondary structure of PSH TMD6a and surrounding residues over simulation time.

(A-C) Secondary structure of PSH TMD6a (orange) and surrounding residues of model 1 (A), model 2 (B) and model 3 (C) in DDM micelle (top) and POPC bilayer (bottom) environments over the simulation time calculated using DSSP algorithm. As indicated, 3 simulations were performed in both environments for each model.

Figure 5 – figure supplement 3. Comparison of model 2 and 3.

(A) Structural comparison of model 2 (blue) and 3 (gray). TMD6a is spatially closer to the C83 substrate in model 2.

(B) Comparison of the backbone RMSFs of PSH model 2 (blue) and 3 (gray) in POPC bilayer averaged over three trajectories. The gray box highlights TMD6a and shaded areas represent the SD of the mean. An enlarged view on backbone RMSF of residues K170 to P185 (including TMD6a) is shown in (C).

(C) Enlarged representation of backbone RMSF of residues K170 to P185 (including TMD6a (orange)) in POPC environment for model 2 (blue) and model 3 (gray) averaged over three trajectories. The shaded areas represent the SD of the mean. Data in (B) and (C) are taken from **Figure 5E** and **Figure 5 – figure supplement 1B** respectively, and are used here as an overlay to allow a direct comparison of model 2 and 3 in POPC bilayer.

Figure 6 – figure supplement 1. Hydrophobic interactions of PS1 TMD6a in substrate-bound and GSI-bound γ -secretases.

(A, B) Interactions between TMD6a of PS1 and substrate residues near the scissile bond(s) in the C83-bound (A) and Notch1 (N100)-bound (B) γ -secretase cryo-EM structures (PDB 6IYC and PDB 6IDF, respectively). The van der Waals radii of

TMD6a and directly surrounding residues (R268 to R278) of PS1 are shown by the gray surface.

(C, D) Interactions between TMD6a of PS1 and GSI in the Semagacestat-bound (C) and L-685,458 bound (D) γ -secretase cryo-EM structures (PDB 6LR4 and PDB 7C9I, respectively). The van der Waals radii of TMD6a and directly surrounding residues (R268 to R278) of PS1 are shown by the gray surface.

Figure 6 – figure supplement 2. Biophysical properties of DDM and POPC.

(A) Structures of DDM and POPC.

(B) Calculated lipid order parameters S_{CH} of the acyl chains of DDM (red) and POPC (sn-1 blue, sn-2 black). Data are represented as mean $\pm$ SD ($n = 3$ trajectories).

(C) Area per lipid of POPC molecules averaged for every 30 ns in model 2.

Figure 6 – figure supplement 3. MD simulations in different DDM micelles.

(A) PSH with bound C83 substrate embedded in a DDM micelle environment (225 DDM molecules).

(B) Calculated lipid order parameters S_{CH} of the acyl chains of DDM in small (red, 150 molecules) and large (olive, 225 molecules) micelles. Data are represented as mean $\pm$ SD ($n = 3$ trajectories).

(C) The average number of H-bonds formed between the β 3-strand of C83 and the β 2-strand of PSH in DDM micelles composed of 150 molecules (red) and 225 molecules (olive). Each data point stands for the average value throughout one trajectory and the error bars represent the SD of the mean of the three data points.

(D) The backbone RMSF of C83 in DDM micelles composed of 150 molecules (red) and 225 molecules (olive) averaged over three trajectories. The shaded areas represent the SD of the mean.

(E) Water accessibility along the substrate TMD residues extracted from the simulations in DDM micelles composed of 150 molecules (red) or 225 molecules (olive) (water accessibility for a residue is obtained as the mean number of water molecules within 5 Å of any atom of the residue). Red arrows indicate the position of the two ϵ -cleavage sites. The error bars represent the SD of the mean ($n = 3$ trajectories).

(F) The backbone RMSF of PSH in DDM micelles composed of 150 molecules (red) and 225 molecules (olive) averaged over three trajectories. The shaded areas represent the SD of the mean. An enlarged view on backbone RMSF of residues K170 to P185 (including TMD6a) is shown in (G).

(G) Enlarged representation of backbone RMSF of residues K170 to P185 (including TMD6a (orange)) in small (red) and large (olive) DDM micelles averaged over three trajectories. The shaded areas represent the SD of the mean.

(H) Orientation of DDM molecules around HL1 and TMD6a in DDM micelles composed of 150 molecules (left, red) and 225 molecules (right, olive).

Figure 7 – figure supplement 1. Secondary structure of lysine-mutant PSH TMD6a and surrounding residues over simulation time.

Secondary structure of PSH TMD6a (orange) and surrounding residues bearing lysine mutants in POPC bilayer environments over simulation time calculated using DSSP.

Figure 8 – figure supplement 1. Cy-Cy distances in PSH homology model.

(A) The average Cy-Cy distances between D162 and D220 of PSH. Each data point stands for the average value throughout one trajectory with the error bar showing the SD of the three independent trajectories.

(B) Frequency of the catalysis-compatible Cy-Cy distance (below 7 Å) in DDM and POPC environments.

(C) Cy-Cy distance measured in DDM (red) and POPC (blue) environments throughout different trajectories (solid, dashed, and dotted lines).

Figure 8 – figure supplement 2. Detailed geometry of the E-S catalytic site.

Detail geometries and distances for the atoms between D162, D220 and C83 L49 at a Cy-Cy distance of 8.2 Å in DDM micelles (A) and 6.8 Å in POPC bilayer (B).

Figure 8 – figure supplement 3. Chemical structures of GSIs.

(A, B) Structures of TSA GSIs L-685,458 (A) and III-31C (B).

(C-F) Structures of non-TSA GSIs DAPT (C), LY411575 (D), Begacestat (E) and MRK-560 (F).

RICH MEDIA FILES

Video 1, 2. Detergent-enzyme interaction in the DDM environment.

600 ns trajectories of PSH (red) in complex with C83 (orange) and nearby DDM molecules. A DDM molecule enters into the gap between TMD2 and TMD6 (Video1) or TMD3 and TMD4 (Video 2). TMD6a switches between a helical and a loop conformation with the interference of the disordered DDM molecule.

Video 3. Lipid-enzyme interaction in the POPC environment.

600 ns trajectory of PSH (blue) in complex with C83 (orange) and nearby POPC molecules. POPC molecules do not enter between TMD gaps and TMD6a remains a stable helix throughout the whole trajectory.

1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067

SOURCE DATA

Figure 1 – Source data 1. Calculated and observed masses for A β species in MALDI-TOF mass spectrometry (Source data for **Figure 1D**).

Figure 2 – Source data 1. Calculated and observed masses for A β , and AICD species in MALDI-TOF mass spectrometry (Source data for **Figure 2C, D**). The differences between calculated and observed masses for AICD species arise from different adducts as specified in the respective tables. The GSI controls in **Figure 2 – figure supplement 2B** show that the observed peaks are specific for AICD species derived from PSH cleavage.

Figure 3 – Source data 1. Raw values of p3 and A β concentrations measured in the ECL-IA and calculated p3-40/p3-42 and A β 40/A β 42 ratios (Source data for **Figure 3B, C**).

Figure 8 – Source data 1. Raw values of immunoblot quantitation (Source data for **Figure 8D**).

REFERENCES

- 1 Erez, E., Fass, D. & Bibi, E. How intramembrane proteases bury hydrolytic reactions in the membrane. *Nature* **459**, 371-378, doi:10.1038/nature08146 (2009).

- 1068 2 Beard, H. A., Barniol-Xicota, M., Yang, J. & Verhelst, S. H. L. Discovery of
1069 cellular roles of intramembrane proteases. *ACS Chem. Biol.* **14**, 2372-2388,
1070 doi:10.1021/acschembio.9b00404 (2019).
- 1071 3 Steiner, H., Tagami, S., Fukumori, A. & Okochi, M. Making the final cut:
1072 pathogenic amyloid- β peptide generation by γ -secretase. *Cell Stress* **2**, 292-
1073 310, doi:10.15698/cst2018.11.162 (2018).
- 1074 4 Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer's disease at 25
1075 years. *EMBO Mol. Med.* **8**, 595-608, doi:10.15252/emmm.201606210 (2016).
- 1076 5 Yang, G., Zhou, R. & Shi, Y. Cryo-EM structures of human γ -secretase. *Curr.*
1077 *Opin. Struct. Biol.* **46**, 55-64, doi:10.1016/j.sbi.2017.05.013 (2017).
- 1078 6 Wolfe, M. S. *et al.* Two transmembrane aspartates in presenilin-1 required for
1079 presenilin endoproteolysis and γ -secretase activity. *Nature* **398**, 513-517,
1080 doi:10.1038/19077 (1999).
- 1081 7 Li, Y. M. *et al.* Photoactivated γ -secretase inhibitors directed to the active site
1082 covalently label presenilin 1. *Nature* **405**, 689-694, doi:10.1038/35015085
1083 (2000).
- 1084 8 Steiner, H. *et al.* Glycine 384 is required for presenilin-1 function and is
1085 conserved in polytopic bacterial aspartyl proteases. *Nat. Cell Biol.* **2**, 848-851,
1086 doi:10.1038/35041097 (2000).
- 1087 9 Steiner, H. *et al.* A loss of function mutation of presenilin-2 interferes with
1088 amyloid β -peptide production and Notch signaling. *J. Biol. Chem.* **274**, 28669-
1089 28673, doi:10.1074/jbc.274.40.28669 (1999).

- 1090 10 Kimberly, W. T., Xia, W., Rahmati, T., Wolfe, M. S. & Selkoe, D. J. The
1091 transmembrane aspartates in presenilin 1 and 2 are obligatory for γ -secretase
1092 activity and amyloid β -protein generation. *J. Biol. Chem.* **275**, 3173-3178,
1093 doi:10.1074/jbc.275.5.3173 (2000).
- 1094 11 Yu, G. *et al.* The presenilin 1 protein is a component of a high molecular
1095 weight intracellular complex that contains β -catenin. *J. Biol. Chem.* **273**,
1096 16470-16475, doi:10.1074/jbc.273.26.16470 (1998).
- 1097 12 Saura, C. A. *et al.* Evidence that intramolecular associations between
1098 presenilin domains are obligatory for endoproteolytic processing. *J. Biol. Chem.*
1099 **274**, 13818-13823, doi:10.1074/jbc.274.20.13818 (1999).
- 1100 13 Weihofen, A., Binns, K., Lemberg, M. K., Ashman, K. & Martoglio, B.
1101 Identification of signal peptide peptidase, a presenilin-type aspartic protease.
1102 *Science* **296**, 2215-2218, doi:10.1126/science.1070925 (2002).
- 1103 14 Ponting, C. P. *et al.* Identification of a novel family of presenilin homologues.
1104 *Hum. Mol. Genet.* **11**, 1037-1044, doi:10.1093/hmg/11.9.1037 (2002).
- 1105 15 Torres-Arancivia, C. *et al.* Identification of an archaeal presenilin-like
1106 intramembrane protease. *PLoS One* **5**, doi:10.1371/journal.pone.0013072
1107 (2010).
- 1108 16 Dang, S. *et al.* Cleavage of amyloid precursor protein by an archaeal
1109 presenilin homologue PSH. *Proc. Natl. Acad. Sci. USA* **112**, 3344-3349,
1110 doi:10.1073/pnas.1502150112 (2015).

1111 17 Naing, S. H. *et al.* Catalytic properties of intramembrane aspartyl protease
1112 substrate hydrolysis evaluated using a FRET peptide cleavage assay. *ACS*
1113 *Chem. Biol.* **10**, 2166-2174, doi:10.1021/acscchembio.5b00305 (2015).

1114 18 Naing, S. H. *et al.* Both positional and chemical variables control in vitro
1115 proteolytic cleavage of a presenilin ortholog. *J. Biol. Chem.* **293**, 4653-4663,
1116 doi:10.1074/jbc.RA117.001436 (2018).

1117 19 Takami, M. *et al.* γ -Secretase: successive tripeptide and tetrapeptide release
1118 from the transmembrane domain of β -carboxyl terminal fragment. *J. Neurosci.*
1119 **29**, 13042-13052, doi:10.1523/JNEUROSCI.2362-09.2009 (2009).

1120 20 Takasugi, N. *et al.* The role of presenilin cofactors in the γ -secretase complex.
1121 *Nature* **422**, 438-441, doi:10.1038/nature01506 (2003).

1122 21 Edbauer, D. *et al.* Reconstitution of γ -secretase activity. *Nat. Cell Biol.* **5**, 486-
1123 488, doi:10.1038/ncb960 (2003).

1124 22 Kimberly, W. T. *et al.* γ -Secretase is a membrane protein complex comprised
1125 of presenilin, nicastrin, Aph-1, and Pen-2. *Proc. Natl. Acad. Sci. USA* **100**,
1126 6382-6387, doi:10.1073/pnas.1037392100 (2003).

1127 23 Li, X. *et al.* Structure of a presenilin family intramembrane aspartate protease.
1128 *Nature* **493**, 56-61, doi:10.1038/nature11801 (2013).

1129 24 Sun, L. *et al.* Structural basis of human γ -secretase assembly. *Proc. Natl.*
1130 *Acad. Sci. USA* **112**, 6003-6008, doi:10.1073/pnas.1506242112 (2015).

1131 25 Bai, X. C. *et al.* An atomic structure of human γ -secretase. *Nature* **525**, 212-
1132 217, doi:10.1038/nature14892 (2015).

1133 26 Zhou, R. *et al.* Recognition of the amyloid precursor protein by human γ -
1134 secretase. *Science* **363**, aaw0930, doi:10.1126/science.aaw0930 (2019).

1135 27 Yang, G. *et al.* Structural basis of Notch recognition by human γ -secretase.
1136 *Nature* **565**, 192-197, doi:10.1038/s41586-018-0813-8 (2019).

1137 28 Bai, X. C., Rajendra, E., Yang, G., Shi, Y. & Scheres, S. H. Sampling the
1138 conformational space of the catalytic subunit of human γ -secretase. *eLife* **4**,
1139 e11182, doi:10.7554/eLife.11182 (2015).

1140 29 Yang, G. *et al.* Structural basis of γ -secretase inhibition and modulation by
1141 small molecule drugs. *Cell* **184**, 521-533 e514, doi:10.1016/j.cell.2020.11.049
1142 (2021).

1143 30 Paschkowsky, S., Oestereich, F. & Munter, L. M. Embedded in the membrane:
1144 How lipids confer activity and specificity to intramembrane proteases. *J.*
1145 *Membr. Biol.* **251**, 369-378, doi:10.1007/s00232-017-0008-5 (2018).

1146 31 Zhou, H., Zhou, S., Walian, P. J. & Jap, B. K. Dependency of γ -secretase
1147 complex activity on the structural integrity of the bilayer. *Biochem. Biophys.*
1148 *Res. Commun.* **402**, 291-296, doi:10.1016/j.bbrc.2010.10.017 (2010).

1149 32 Shearman, M. S. *et al.* L-685,458, an aspartyl protease transition state mimic,
1150 is a potent inhibitor of amyloid β -protein precursor γ -secretase activity.
1151 *Biochemistry* **39**, 8698-8704., doi:10.1021/bi0005456 (2000).

1152 33 Osenkowski, P., Ye, W., Wang, R., Wolfe, M. S. & Selkoe, D. J. Direct and
1153 potent regulation of γ -secretase by its lipid microenvironment. *J. Biol. Chem.*
1154 **283**, 22529-22540, doi:10.1074/jbc.M801925200 (2008).

- 1155 34 Osawa, S. *et al.* Phosphoinositides suppress γ -secretase in both the
1156 detergent-soluble and -insoluble states. *J. Biol. Chem.* **283**, 19283-19292,
1157 doi:10.1074/jbc.M705954200 (2008).
- 1158 35 Holmes, O., Paturi, S., Ye, W., Wolfe, M. S. & Selkoe, D. J. Effects of
1159 membrane lipids on the activity and processivity of purified γ -secretase.
1160 *Biochemistry* **51**, 3565-3575, doi:10.1021/bi300303g (2012).
- 1161 36 Winkler, E. *et al.* Generation of Alzheimer disease-associated amyloid β 42/43
1162 peptide by γ -secretase can be inhibited directly by modulation of membrane
1163 thickness. *J. Biol. Chem.* **287**, 21326-21334, doi:10.1074/jbc.M112.356659
1164 (2012).
- 1165 37 Quintero-Monzon, O. *et al.* Dissociation between the processivity and total
1166 activity of γ -secretase: implications for the mechanism of Alzheimer's disease-
1167 causing presenilin mutations. *Biochemistry* **50**, 9023-9035,
1168 doi:10.1021/bi2007146 (2011).
- 1169 38 Lichtenthaler, S. F., Haass, C. & Steiner, H. Regulated intramembrane
1170 proteolysis--lessons from amyloid precursor protein processing. *J Neurochem*
1171 **117**, 779-796, doi:10.1111/j.1471-4159.2011.07248.x (2011).
- 1172 39 Kucerka, N., Nieh, M. P. & Katsaras, J. Fluid phase lipid areas and bilayer
1173 thicknesses of commonly used phosphatidylcholines as a function of
1174 temperature. *Biochim Biophys Acta* **1808**, 2761-2771,
1175 doi:10.1016/j.bbamem.2011.07.022 (2011).
- 1176 40 Sun, L., Zhou, R., Yang, G. & Shi, Y. Analysis of 138 pathogenic mutations in
1177 presenilin-1 on the in vitro production of A β 42 and A β 40 peptides by γ -

1178 secretase. *Proc Natl Acad Sci U S A* **114**, E476-E485,
1179 doi:10.1073/pnas.1618657114 (2017).

1180 41 Chen, S. Y. & Zacharias, M. How mutations perturb γ -secretase active site
1181 studied by free energy simulations. *ACS Chem. Neurosci.*,
1182 doi:10.1021/acscchemneuro.0c00440 (2020).

1183 42 Behr, D. *et al.* In vitro characterization of the presenilin-dependent gamma-
1184 secretase complex using a novel affinity ligand. *Biochemistry* **42**, 8133-8142,
1185 doi:10.1021/bi034045z (2003).

1186 43 Esler, W. P. *et al.* Activity-dependent isolation of the presenilin- γ -secretase
1187 complex reveals nicastrin and a γ substrate. *Proc. Natl. Acad. Sci. USA* **99**,
1188 2720-2725, doi:10.1073/pnas.052436599052436599 [pii] (2002).

1189 44 Dovey, H. F. *et al.* Functional γ -secretase inhibitors reduce β -amyloid peptide
1190 levels in brain. *J. Neurochem.* **76**, 173-181., doi:10.1046/j.1471-
1191 4159.2001.00012.x (2001).

1192 45 Lanz, T. A., Hosley, J. D., Adams, W. J. & Merchant, K. M. Studies of A β
1193 pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young
1194 (plaque-free) Tg2576 mice using the γ -secretase inhibitor N2-[(2S)-2-(3,5-
1195 difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-di hydro-5H-
1196 dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). *J Pharmacol Exp Ther*
1197 **309**, 49-55, doi:10.1124/jpet.103.060715 (2004).

1198 46 Mayer, S. C. *et al.* Discovery of begacestat, a Notch-1-sparing γ -secretase
1199 inhibitor for the treatment of Alzheimer's disease. *J. Med. Chem.* **51**, 7348-
1200 7351, doi:10.1021/jm801252w (2008).

1201 47 Best, J. D. *et al.* In vivo characterization of A β (40) changes in brain and
1202 cerebrospinal fluid using the novel γ -secretase inhibitor N-[cis-4-[(4-
1203 chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoro-
1204 uoromethanesulfonamide (MRK-560) in the rat. *J Pharmacol Exp Ther* **317**,
1205 786-790, doi:10.1124/jpet.105.100271 (2006).

1206 48 Hitzenberger, M. & Zacharias, M. Uncovering the binding mode of γ -secretase
1207 Inhibitors. *ACS Chem. Neurosci.* **10**, 3398-3403,
1208 doi:10.1021/acscchemneuro.9b00272 (2019).

1209 49 Mehra, R., Dehury, B. & Kepp, K. P. Cryo-temperature effects on membrane
1210 protein structure and dynamics. *Phys. Chem. Chem. Phys.* **22**, 5427-5438,
1211 doi:10.1039/c9cp06723j (2020).

1212 50 Bhattarai, A., Devkota, S., Bhattarai, S., Wolfe, M. S. & Miao, Y. Mechanisms
1213 of γ -secretase activation and substrate processing. *ACS Cent. Sci.* **6**, 969-983,
1214 doi:10.1021/acscentsci.0c00296 (2020).

1215 51 Okochi, M. *et al.* γ -Secretase modulators and presenilin 1 mutants act
1216 differently on presenilin/ γ -secretase function to cleave A β 42 and A β 43. *Cell*
1217 *Rep.* **3**, 42-51, doi:10.1016/j.celrep.2012.11.028 (2013).

1218 52 Dehury, B., Tang, N. & Kepp, K. P. Molecular dynamics of C99-bound γ -
1219 secretase reveal two binding modes with distinct compactness, stability, and
1220 active-site retention: implications for A β production. *Biochem. J.* **476**, 1173-
1221 1189, doi:10.1042/BCJ20190023 (2019).

1222 53 Szaruga, M. *et al.* Alzheimer's-causing mutations shift A β length by
1223 destabilizing γ -secretase-A β n Interactions. *Cell* **170**, 443-456 e414,
1224 doi:10.1016/j.cell.2017.07.004 (2017).

1225 54 Somavarapu, A. K. & Kepp, K. P. Loss of stability and hydrophobicity of
1226 presenilin 1 mutations causing Alzheimer's disease. *J. Neurochem.* **137**, 101-
1227 111, doi:10.1111/jnc.13535 (2016).

1228 55 Tang, N., Dehury, B. & Kepp, K. P. Computing the Pathogenicity of
1229 Alzheimer's Disease Presenilin 1 Mutations. *J. Chem. Inf. Model* **59**, 858-870,
1230 doi:10.1021/acs.jcim.8b00896 (2019).

1231 56 Fukumori, A. & Steiner, H. Substrate recruitment of γ -secretase and
1232 mechanism of clinical presenilin mutations revealed by photoaffinity mapping.
1233 *EMBO J.* **35**, 1628-1643, doi:10.15252/emj.201694151 (2016).

1234 57 Trambauer, J. *et al.* A β 43-producing PS1 FAD mutants cause altered
1235 substrate interactions and respond to γ -secretase modulation. *EMBO Rep.* **21**,
1236 e47996, doi:10.15252/embr.201947996 (2020).

1237 58 Hu, J., Xue, Y., Lee, S. & Ha, Y. The crystal structure of GXGD membrane
1238 protease FlaK. *Nature* **475**, 528-531, doi:10.1038/nature10218 (2011).

1239 59 Shirotani, K., Tomioka, M., Kremmer, E., Haass, C. & Steiner, H. Pathological
1240 activity of familial Alzheimer's disease-associated mutant presenilin can be
1241 executed by six different γ -secretase complexes. *Neurobiol. Dis.* **27**, 102-107
1242 (2007).

- 1243 60 Winkler, E. *et al.* Purification, pharmacological modulation, and biochemical
1244 characterization of interactors of endogenous human γ -secretase.
1245 *Biochemistry* **48**, 1183-1197, doi:10.1021/bi801204g (2009).
- 1246 61 Page, R. M. *et al.* Generation of A β 38 and A β 42 is independently and
1247 differentially affected by FAD-associated presenilin 1 mutations and γ -
1248 secretase modulation. *J. Biol. Chem.* **283**, 677-683 (2008).
- 1249 62 Ebke, A. *et al.* Novel γ -secretase enzyme modulators directly target presenilin
1250 protein. *J. Biol. Chem.* **286**, 37181-37186, doi:10.1074/jbc.C111.276972
1251 (2011).
- 1252 63 Waterhouse, A. *et al.* SWISS-MODEL: homology modelling of protein
1253 structures and complexes. *Nucleic Acids Res.* **46**, W296-W303,
1254 doi:10.1093/nar/gky427 (2018).
- 1255 64 Eswar, N. *et al.* Comparative protein structure modeling using Modeller. *Curr.*
1256 *Protoc. Bioinformatics* **Chapter 5**, Unit-5 6,
1257 doi:10.1002/0471250953.bi0506s15 (2006).
- 1258 65 Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M.
1259 L. Comparison of simple potential functions for simulating liquid water. *J.*
1260 *Chem. Phys.* **79**, 926-935 (1983).
- 1261 66 Cheng, X., Jo, S., Lee, H. S., Klauda, J. B. & Im, W. CHARMM-GUI micelle
1262 builder for pure/mixed micelle and protein/micelle complex systems. *J. Chem.*
1263 *Inf. Model* **53**, 2171-2180, doi:10.1021/ci4002684 (2013).

- 1264 67 Wu, E. L. *et al.* CHARMM-GUI Membrane Builder toward realistic biological
1265 membrane simulations. *J. Comput. Chem.* **35**, 1997-2004,
1266 doi:10.1002/jcc.23702 (2014).
- 1267 68 Huang, J. *et al.* CHARMM36m: an improved force field for folded and
1268 intrinsically disordered proteins. *Nat. Methods* **14**, 71-73,
1269 doi:10.1038/nmeth.4067 (2017).
- 1270 69 Case, D. A. *et al.* The Amber biomolecular simulation programs. *J. Comput.*
1271 *Chem.* **26**, 1668-1688, doi:10.1002/jcc.20290 (2005).
- 1272 70 Olsson, M. H., Sondergaard, C. R., Rostkowski, M. & Jensen, J. H.
1273 PROPKA3: Consistent treatment of internal and surface residues in empirical
1274 pKa predictions. *J. Chem. Theory Comput.* **7**, 525-537, doi:10.1021/ct100578z
1275 (2011).
- 1276 71 Tieleman, D. P., Marrink, S. J. & Berendsen, H. J. A computer perspective of
1277 membranes: molecular dynamics studies of lipid bilayer systems. *Biochim.*
1278 *Biophys. Acta* **1331**, 235-270, doi:10.1016/s0304-4157(97)00008-7 (1997).
- 1279 72 Vermeer, L. S., de Groot, B. L., Reat, V., Milon, A. & Czaplicki, J. Acyl chain
1280 order parameter profiles in phospholipid bilayers: computation from molecular
1281 dynamics simulations and comparison with ²H NMR experiments. *Eur.*
1282 *Biophys. J.* **36**, 919-931, doi:10.1007/s00249-007-0192-9 (2007).
- 1283 73 Kabsch, W. & Sander, C. Dictionary of protein secondary structure: pattern
1284 recognition of hydrogen-bonded and geometrical features. *Biopolymers* **22**,
1285 2577-2637, doi:10.1002/bip.360221211 (1983).
- 1286

Figure 1

Figure 1

Figure 1 – figure supplement 1

Figure 2

Figure 2 – figure supplement 1

Figure 2 – figure supplement 2

Figure 3

Figure 4

B

RMSD (Å)	4HYG (Chain B)	4Y6K (Chain B)	Model 1	Model 2	Model 3
4HYG (Chain B)	0				
4Y6K (Chain B)	0.349	0			
Model 1	3.379	3.349	0		
Model 2	1.153	1.602	1.355	0	
Model 3	1.416	1.513	1.484	0.163	0

Figure 4 – figure supplement 1

Figure 5

Figure 5 – figure supplement 1

Figure 5 – figure supplement 2

Figure 5 – figure supplement 3

Figure 6

Figure 6 – figure supplement 1

Figure 6 – figure supplement 2

Figure 6 – figure supplement 3

Figure 7

Figure 7

Figure 7 – figure supplement 1

Figure 8

Figure 8

Figure 8 – figure supplement 1

Distance (Å)	D162-O1	D162-O2	D220 ^H -O1	D220 ^H -O2	D220 ^H -H2
L49-C	7.53	5.94	3.75	3.72	2.86
L49-O	6.64	5.29	3.46	2.86	1.93
D162-O1	0	0	9.10	7.07	6.85
D162-O2	0	0	8.21	6.43	5.99

Distance (Å)	D162-O1	D162-O2	D220 ^H -O1	D220 ^H -O2	D220 ^H -H2
L49-C	6.16	5.02	4.31	3.67	2.72
L49-O	6.19	5.44	3.75	2.69	1.77
D162-O1	0	0	4.88	6.57	6.14
D162-O2	0	0	5.29	6.61	5.93

Figure 8 – figure supplement 2

A L-685,458

B III-31C

C DAPT

D LY411575

E Begacestat

F MRK-560

Figure 8 – figure supplement 3

Table 1. Templates used for model building of PSH in complex with C83.

	Template		
	6IYC (PS1, C83)	4HYG (Chain B)	Model 1
Model 1	*	—	—
Model 2	—	L7-D162, D220-L292	complete
Model 3	—	L7-A176, E210-A293	complete

* PSH residues L7-R193 and E210-A293 were modeled based on the template.

Table 2. pKa predictions as calculated by PROPKA3.1 for published PSH and γ -secretase structures.

PDB ID	Enzyme	Ligand	pKa (D162, D220)
4HYG	PSH	None	5.04, 6.62
4Y6K	PSH	III-31-C	5.63, 7.52

PDB ID	Enzyme	Ligand	pKa (D257, D385)
4UIS	PS1	None	3.18, 6.16
5A63	PS1	None	4.42, 6.16
5FN5	PS1	None	4.98, 3.63
5FN4	PS1	Unknown helix	4.70, 4.71
5FN3	PS1	Unknwon helix	4.90, 7.13
5FN2	PS1	DAPT	5.13, 9.93
6IYC	PS1	C83	6.39, X*
6IDF	PS1	Notch1	6.21, X*
6LR4	PS1	Semagacestat	6.12, 7.94
6LQG	PS1	Avagacestat	6.08, 7.22
7V9I	PS1	L-685,458	7.11, 8.90
7D8X	PS1	L-685,458 & E2012	7.01, 8.69

* For structure determination D385 was mutated to alanine and therefore no pKa value is given.